Hinova Pharmaceuticals, Inc. Class ASSE: 688302

Announcement on Voluntary Disclosure of Interim Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Interim Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Hinova Pharmaceuticals, Inc. Class A

All Hinova Pharmaceuticals, Inc. Class A news releases